InnoCare Pharma Limited (HKG:9969)
10.85
+0.07 (0.65%)
Jun 26, 2026, 4:08 PM HKT
InnoCare Pharma Employees
InnoCare Pharma had 1,176 employees as of June 30, 2025. The number of employees increased by 87 or 7.99% compared to the previous year.
Employees
1,176
Change
87
Growth
7.99%
Revenue / Employee
2.44M HKD
Profits / Employee
705.89K HKD
Market Cap
23.32B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Genscript Biotech | 6,165 |
| Keymed Biosciences | 1,625 |
| Shanghai Junshi Biosciences | 2,903 |
| Shanghai Henlius Biotech | 3,762 |
| Zai Lab | 1,784 |
| Duality Biotherapeutics | 231 |
| 3SBio | 6,109 |
| Biocytogen Pharmaceuticals (Beijing) | 1,443 |
InnoCare Pharma News
- 23 days ago - Phase IIb Study Results of InnoCare's Orelabrutinib in Patients with SLE Presented at 2026 EULAR - GlobeNewsWire
- 25 days ago - ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released - GlobeNewsWire
- 4 weeks ago - InnoCare Pharma upgraded to Overweight from Equal Weight at Morgan Stanley - TheFly
- 4 weeks ago - InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China - GlobeNewsWire
- 4 weeks ago - InnoCare Announces Approval of Orelabrutinib in Australia - GlobeNewsWire
- 5 weeks ago - 2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released - GlobeNewsWire
- 6 weeks ago - InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor - GlobeNewsWire
- 7 weeks ago - InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China - GlobeNewsWire